InvestorsHub Logo
Followers 51
Posts 9104
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Sunday, 12/04/2022 1:23:24 AM

Sunday, December 04, 2022 1:23:24 AM

Post# of 13480
Moderna is expecting primary data from the 157-participant KEYNOTE-942 trial this quarter. Patients in the study received up to nine doses of mRNA-4157 at 21-day intervals.

RELAX$
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News